Skip to main content

Table 1 Baseline characteristics

From: Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity

 

Abdominal obesity

p value

(−) group

(+) group

n

28

60

 

Males/Females

13/15

38/22

0.167

Age, years

55.7 ± 6.7

54.8 ± 7.3

0.575

Body mass index, kg/m2

20.9 ± 2.3

28.7 ± 4.8

<0.01

Duration of diabetes mellitus, years

11.6 ± 10.3

9.1 ± 7.8

0.216

Number of hospitalizations

1.7 ± 0.9

2.3 ± 2.0

0.176

Family history of diabetes mellitus, %

61

53

0.646

Fasting plasma glucose, mg/dL

154 ± 56

153 ± 50

0.951

Hemoglobin A1c (NGSP), % (mmol/mol)

9.3 ± 2.2 (78)

9.1 ± 1.9 (76)

0.648

Fasting insulin, IU/L

4.6 ± 2.9

9.9 ± 8.4

<0.01

Fasting C-peptide, ng/mL

1.5 ± 0.9

2.0 ± 1.0

<0.05

HOMA-IR

1.5 ± 1.0 (n = 18)

3.4 ± 3.5 (n = 30)

<0.05

Maximum carotid IMT, mm

1.4 ± 0.7

1.6 ± 1.0

0.345

Diabetic retinopathy (NDR/SDR/PPDR/PDR)

16/5/0/7

41/7/3/8

0.250

Diabetic nephropathy (normo/micro/overt)

21/5/2

44/9/6

0.814

Discharge medications for diabetes mellitus

   

Sulfonylurea, %

32

20

0.283

Biguanide, %

7

40

<0.01

Thiazolidinedione, %

14

12

0.738

Alpha-glucosidase inhibitor, %

18

15

0.760

Glinide, %

0

5

0.548

Dipeptidyl peptidase-4 inhibitor, %

18

27

0.431

Glucagon-like peptide-1 analog, %

0

8

0.173

Insulin, %

54

38

0.248

  1. Data are mean ± SD, number of subjects or frequency [n (%)],
  2. NGSP national glycohemoglobin standardization program, HOMA-IR homeostasis model assessment of insulin resistance, IMT intima-media thickness, NDR non-diabetic retinopathy, SDR simple diabetic retinopathy, PPDR preproliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, normo normoalbuminuria, micro microalbuminuria, overt overt proteinuria.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840